Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.

IF 3.5 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

AMB Express Pub Date : 2025-03-12 DOI:10.1186/s13568-025-01837-1

Ann A Elshamy, Sandra K Kamal, Mariam T Mahmoud, Aya M Elhasany, Aya A Shady, Sherok A Mohamed, Hasna A Abd-Elmaaboud, Nour E El-Awady, Rana A Mohamed, Sara A El-Mirghany, Sarraa W El-Hady, Mohamed M Abd-ElRahman, Khaled M Aboshanab

{"title":"Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.","authors":"Ann A Elshamy, Sandra K Kamal, Mariam T Mahmoud, Aya M Elhasany, Aya A Shady, Sherok A Mohamed, Hasna A Abd-Elmaaboud, Nour E El-Awady, Rana A Mohamed, Sara A El-Mirghany, Sarraa W El-Hady, Mohamed M Abd-ElRahman, Khaled M Aboshanab","doi":"10.1186/s13568-025-01837-1","DOIUrl":null,"url":null,"abstract":"<p><p>Acinetobacter baumannii is a prevalent clinical pathogen commonly found to be multidrug-resistant (MDR), causing serious to life-threatening infections, particularly hospital-acquired infections with limited therapeutic options. The MDR phenotype developed against this critical pathogen is increasingly developed globally, reaching a pan-drug-resistant phenotype conferring non-susceptibility to all antimicrobials used in its treatment according to the standard guidelines. Therefore, it is critical to develop innovative treatment approaches, such as phage therapy, considering the rise in drug-resistant A. baumannii infections. In this review, we highlight and discuss the up-to-date antimicrobial resistance of A. baumannii, the use of phages, their limitations, and future perspectives in treating A. baumannii infections. In addition, the combination of phages with antimicrobials, preclinical and clinical studies including pharmacokinetics and pharmacodynamics properties have been discussed.</p>","PeriodicalId":7537,"journal":{"name":"AMB Express","volume":"15 1","pages":"44"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904003/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AMB Express","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s13568-025-01837-1","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Acinetobacter baumannii is a prevalent clinical pathogen commonly found to be multidrug-resistant (MDR), causing serious to life-threatening infections, particularly hospital-acquired infections with limited therapeutic options. The MDR phenotype developed against this critical pathogen is increasingly developed globally, reaching a pan-drug-resistant phenotype conferring non-susceptibility to all antimicrobials used in its treatment according to the standard guidelines. Therefore, it is critical to develop innovative treatment approaches, such as phage therapy, considering the rise in drug-resistant A. baumannii infections. In this review, we highlight and discuss the up-to-date antimicrobial resistance of A. baumannii, the use of phages, their limitations, and future perspectives in treating A. baumannii infections. In addition, the combination of phages with antimicrobials, preclinical and clinical studies including pharmacokinetics and pharmacodynamics properties have been discussed.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

AMB Express BIOTECHNOLOGY & APPLIED MICROBIOLOGY-

CiteScore

7.20

自引率

2.70%

发文量

141

审稿时长

13 weeks

期刊介绍： AMB Express is a high quality journal that brings together research in the area of Applied and Industrial Microbiology with a particular interest in ''White Biotechnology'' and ''Red Biotechnology''. The emphasis is on processes employing microorganisms, eukaryotic cell cultures or enzymes for the biosynthesis, transformation and degradation of compounds. This includes fine and bulk chemicals, polymeric compounds and enzymes or other proteins. Downstream processes are also considered. Integrated processes combining biochemical and chemical processes are also published.